Rigel Pharmaceuticals, Inc. (RIGL) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$26.67
Price Target
$40.00
Target Range
$38.00 — $42.00
Analyst Rating
Buy
Forward P/E6.1x
Trailing P/E1.4x
Forward PEG—
Implied Growth-76.5%
Median Target$40.00
Analyst Spread10.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$38
+42.5%
Consensus
$40
+50.0%
Bull Case
$42
+57.5%
RIGL Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Rigel Pharmaceuticals, Inc. (RIGL) has a Wall Street consensus price target of $40.00, based on estimates from 15 covering analysts. With the stock currently trading at $26.67, this represents a potential upside of +50.0%. The company has a market capitalization of $493M.
Analyst price targets range from a low of $38.00 to a high of $42.00, representing a 10% spread in expectations. The median target of $40.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, RIGL trades at a trailing P/E of 1.4x and forward P/E of 6.1x. Analysts expect EPS to grow -76.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+76.2%
Avg Forward P/E46.7x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PRTAProthena Corporation plc | $602M | $11.18 | $19.00 | +69.9% | Buy | 45.3x | 28 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 RAREUltragenyx Pharmaceutical Inc. | $2.5B | $25.93 | $51.50 | +98.6% | Buy | — | 33 |
 HALOHalozyme Therapeutics, Inc. | $7.8B | $66.35 | $78.33 | +18.1% | Buy | 8.2x | 27 |
 PTCTPTC Therapeutics, Inc. | $5.5B | $66.61 | $89.67 | +34.6% | Buy | — | 26 |
 ACADACADIA Pharmaceuticals Inc. | $3.7B | $21.48 | $34.78 | +61.9% | Buy | 48.5x | 37 |
 IMVTImmunovant, Inc. | $5.8B | $28.67 | $45.50 | +58.7% | Buy | — | 23 |
 ARQTArcutis Biotherapeutics, Inc. | $3.0B | $24.17 | $35.50 | +46.9% | Buy | 90.8x | 12 |
 CABACabaletta Bio, Inc. | $381M | $3.73 | $16.33 | +337.8% | Buy | — | 12 |
 KYMRKymera Therapeutics, Inc. | $7.0B | $86.26 | $117.06 | +35.7% | Buy | — | 26 |
Upside Potential Comparison
CABARAREPRTAACADIMVTARQTKYMRPTCTSee RIGL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RIGL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RIGL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRIGL — Frequently Asked Questions
Quick answers to the most common questions about buying RIGL stock.
What is the RIGL stock price target for 2026?
The consensus Wall Street price target for RIGL is $40, representing 50.0% upside from the current price of $26.67. With 15 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is RIGL a buy, sell, or hold?
RIGL has a consensus rating of "Buy" based on 15 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $40 implies 50.0% upside from current levels.
Is RIGL stock overvalued or undervalued?
With a forward P/E of 6.1401x, RIGL trades at a relatively low valuation. The consensus target of $40 implies 50.0% appreciation, suggesting meaningful undervaluation.
How high can RIGL stock go?
The most bullish Wall Street analyst has a price target of $42 for RIGL, while the most conservative target is $38. The consensus of $40 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover RIGL stock?
RIGL is well covered by analysts, with 15 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 7 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the RIGL stock forecast?
The 12-month RIGL stock forecast based on 15 Wall Street analysts shows a consensus price target of $40, with estimates ranging from $38 (bear case) to $42 (bull case). The median consensus rating is "Buy".
What is RIGL's forward P/E ratio?
RIGL trades at a forward P/E ratio of 6.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 1.4x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy RIGL stock?
Wall Street analysts are very optimistic on RIGL, with a "Buy" consensus rating and $40 price target (50.0% upside). 8 of 15 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do RIGL price targets vary so much?
RIGL analyst price targets range from $38 to $42, a 10% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $40 consensus represents the middle ground.